0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Reducing High Blood Cholesterol Levels With Drugs

Bruce A. Boselli, MD
JAMA. 1991;265(15):1949-1950. doi:10.1001/jama.1991.03460150053013.
Text Size: A A A
Published online

To the Editor.—  The recent article by Schulman et al1 considers the cost-effectiveness of the use of several lipid-altering agents for the treatment of hypercholesterolemia, with the ultimate goal of reducing the risk for the development of coronary heart disease. Acknowledging that we, as the manufacturer of one of the pharmacologic agents (gemfibrozil) mentioned in this article, have a vested interest in the published results by Schulman et al, we nonetheless believe that certain issues in this study need to be addressed.The authors assumed that all of the lipid-regulating agents (ie, cholestyramine resin, colestipol hydrochloride, gemfibrozil, lovastatin, niacin, and probucol) used in their analyses have been proved to be effective in reducing the risk of coronary heart disease. We believe this assumption cannot be presently supported from the published literature. Only cholestyramine resin2 and gemfibrozil3,4 have undergone long-term primary prevention trials that demonstrated their safety and

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();